Weight Loss Injections and Enhanced Fertility

Recent findings suggest that weight loss injections, particularly GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro, can enhance fertility in overweight women, including those with polycystic ovary syndrome (PCOS). These medications work by promoting weight loss, improving insulin sensitivity, and stabilizing hormonal balance.

While they show promise in increasing the likelihood of pregnancies, close medical supervision is essential to mitigate risks, particularly during pregnancy and breastfeeding. There are concerns about potential complications, emphasizing the need for personalized medical advice.

Simultaneously, Novo Nordisk, the manufacturer of these injections, is expanding its production capacity due to surging demand. However, this growth has sparked criticism related to supply shortages and safety issues, underscoring the importance of careful management in the use of these treatments.